[1]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.[2]LAI CL, RATZIU V, YUEN MF, et al.Viral hepatitis B[J].Lancet, 2003, 362 (9401) :2089-2094.[3]Lamivudine Clinical Practice Group.Lamivudine treatment consensus from relative experts in 2004[J].J Clin Hepatol, 2005, 8 (1) :60-64. (in Chinese) 拉米夫定临床应用专家组.拉米夫定临床应用专家共识 (2004年版) [J].实用肝脏病杂志, 2005, 8 (1) :60-64.[4]QIN H, CHENG XF, TENG X, et al.Study mutation in Heilongjiang province[J].Int J Virol, 2012, 19 (1) :15-19. (in Chinese) 秦辉, 程险峰, 滕旭, 等.黑龙江省乙型肝炎病毒拉米夫定耐药株YMDD变异与基因型、BCP区变异的相关性研究[J].国际病毒学杂志, 2012, 19 (1) :15-19.[5]USUDA S, OKAMOTO H, TSUDA F, et al.An enzyme-linked immunosorbent assay with monoclonal antibodies for the determination of phosphorylated hepatitis B core protein (p21c) in serum[J].J Virol Methods, 1998, 72 (1) :95-103.[6]KIMURA, TA, ROKUHARA Y, SAKAMOTO S, et al.Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J].J Clin Microbiol, 2002, 40 (2) :439-445.[7]Chinese Society of Infectious and Parasitic Diseases, Chinese Society of Hepatology.Prevention and treatment programs in viral hepatitis[J].Chin J Hepatol, 2000, 8 (6) :324-329. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) :324-329.[8]MARZANO A, GAIA S, GHISETTI V, et al.Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence[J].Liver Transpl, 2005, 11 (4) :402-409.[9]WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126 (7) :1750-1758.[10]LOK ASF, McMAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :1-36.[11]YUEN MF, WONG DK, SUM SS, et al.Effect of lamivudine therapy on the serum covalently closed circular (ccc) DNA of chronic hepatitis B infection[J].Am J Gastroenterol, 2005, 100 (5) :1099-1110.[12]HAMADA R, NAKAO R, HAI N, et al.Hepatitis B virus corerelated antigen as an indicator of safe discontinuation of lamivudine therapy[J].Hepatology, 2006, 44 (4) :562a.[13]LIU C, MU YP, YANG ZG, et al.Clinical significance of monitoring hepatitis B virus core-related antigens[J].J Clin Hepatol, 2012, 28 (10) :793-796. (in Chinese) 刘成, 慕永平, 杨宗国, 等.乙型肝炎病毒核心相关抗原的监测及临床意义[J].临床肝胆病杂志, 2012, 28 (10) :793-796.[14]MATSUMOTO A, TANAKA E, SUZUKI Y, et al.Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B[J].Hepatol Res, 2012, 42 (2) :139-149.
|